A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Phase 2

LinaclotideA Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Sponsor:

AbbVie

Code:

NCT05760313

Conditions

Functional Constipation

Eligibility Criteria

Sex: All

Age: 6 - 23

Healthy Volunteers: Not accepted

Interventions

Linaclotide

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by AbbVie on 2025-05-21.